Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited announced its total issued share capital as of September 30, 2025, comprising 872,148,995 ordinary shares, each with one voting right. This information is crucial for shareholders to determine their notification requirements under the Financial Conduct Authority’s rules, impacting their interest calculations in HUTCHMED shares.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
For a thorough assessment of 0013 stock, go to TipRanks’ Stock Analysis page.